Dominique V, Antje P, Hilario N, et al. Sarcoidosis[J]. Lancet, 2014, 383(9923):1155-1167.
[2]
Leonhard S E, Fritz D, Eftimov F, et al. Neurosarcoidosis in a Tertiary Referral Center: a cross-sectional cohort study[J]. Medicine, 2016, 95(14):e3277.
[3]
Ca??o G, Branco A, Meireles M, et al. Neurosarcoidosis according to Zajicek and Scolding criteria: 15 probable and definite cases, their treatment and outcomes[J]. J Neurol Sci, 2017, 379:84-88.
[4]
James D G, Sharma O P. From Hutchinson to now: a historical glimpse[J]. Curr Opin Pulm Med, 2002, 8(5):416-423.
[5]
Hebel R, Dubaniewicz A. Overview of neurosarcoidosis: recent advances [J]. J Neurol, 2015, 262(2):258-267.
[6]
Radwan W, Luckewold B, Robadi I A, et al. Neurosarcoidosis: unusual presentations and considerations for diagnosis and management[J]. Postgrad Med J, 2017, 93(1101):401-405.
[7]
Iannuzzi M C, Rybicki B A, Teirstein A S. Sarcoidosis[J]. New Engl J Med, 2007, 357(21):2153-2165.
[8]
Nowak D A, Widenka D C. Neurosarcoidosis: a review of its intracranial manifestation [J]. J Neurol, 2001, 248(5):363-372.
[9]
Darlington P, Gabrielsen A, Soerensson P, et al. HLA-alleles associated with increased risk for extra-pulmonary involvement in sarcoidosis [J].HLA, 2014, 83(4):267-272.
[10]
Fritz D, Voortman M, Vand B D, et al. Many faces of neurosarcoidosis: from chronic meningitis to myelopathy [J]. Curr Opin Pulm Med, 2017, 23(5):439-446.
[11]
Negi M, Takemura T, Guzman J, et al. Localization of propionibacterium acnes in granulomas supports a possible etiologic link between sarcoidosis and the bacterium[J]. Modern Pathol, 2012, 25(9):1284-1297.
[12]
Akimoto J, Nagai K, Ogasawara D, et al. Solitary tentorial sarcoid granuloma associated with Propionibacterium acnes infection: case report [J].J Neurosurg,2017,127(3):687-690.
[13]
Carlson M L, White J R Jr, Espahbodi M, et al. Cranial base manifestations of neurosarcoidosis: a review of 305 patients[J]. Otol Neurotol,2015,36(1):156-166.
[14]
Cohen-Aubart F, Galanaud D, Grabli D, et al. Spinal cord sarcoidosis: clinical and laboratory profile and outcome of 31 patients in a case-control study[J]. Medicine, 2010, 89(2):133-140.
[15]
Ginat D T, Gurpreet D, Jeevak A. Magnetic resonance imaging of neurosarcoidosis[J]. J Clin Imaging Sci, 2011, 1(1):15-21.
[16]
Benzagmout M, Boujraf S, Góngora-Rivera F, et al. Neurosarcoidosis which manifested as acute hydrocephalus: diagnosis and treatment [J]. Internal Med, 2007, 46(18):1601-1604.
[17]
Said G, Lacroix C, Planté-bordeneuve V, et al. Nerve granulomas and vasculitis in sarcoid peripheral neuropathy: a clinicopathological study of 11 patients[J]. Brain, 2002, 125(Pt 2):264-275.
[18]
Fritz D, Vand B D, Brouwer M C. Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta-analysis [J]. BMC Neurol, 2016, 16(1):220-227.
[19]
Pawate S, Moses H, Sriram S. Presentations and outcomes of neurosarcoidosis: a study of 54 cases[J]. QJM, 2009, 102(7):449-460.
[20]
Mostard R L, Van Kroonenburgh M J, Drent M. The role of the PET scan in the management of sarcoidosis [J]. Curr Opin Pulm Med, 2013, 19(5):538-544.
[21]
Spiegel D R, Morris K, Rayamajhi U. Neurosarcoidosis and the complexity in its differential diagnoses: a review [J]. ICNS, 2012, 9(4):10-16.
[22]
Petereit H F, Reske D, Tumani H, et al. Soluble CSF interleukin 2 receptor as indicator of neurosarcoidosis[J]. J Neurol, 2010, 257(11):1855-1863.
[23]
Wegener S, Linnebank M, Martin R, et al. Clinically isolated neurosarcoidosis: a recommended diagnostic path[J]. Eur Neurol, 2015, 73(1-2):71-77.
[24]
Burns T M, Dyck P J, Aksamit A J, et al. The natural history and long-term outcome of 57 limb sarcoidosis neuropathy cases [J]. J Neurol Sci, 2006, 244(1-2):77-87.
[25]
Joseph F G, Scolding N J. Neurosarcoidosis: a study of 30 new cases [J]. J Neurol Neurosurg Psychiatry, 2009, 80(3): 297-304.
[26]
Zajicek J P, Scolding N J, Foster O, et al. Central nervous system sarcoidosis-diagnosis and management[J]. QJM, 1999, 92(2):103-117.
[27]
Judson M A, Costabel U, Drent M, et al. The WASOG Sarcoidosis Organ Assessment Instrument: an update of a previous clinical tool [J]. Sarcoidosis Vasc Diffuse Lung Dis, 2014, 31(1):19-27.
[28]
Brito-Zerón P, Pérez-Alvarez R, Pallarés L, et al. Sarcoidosis: an update on current pharmacotherapy options and future directions [J]. Expert Opin Pharmaco, 2016, 17(18):2431-2448.
[29]
Nozaki K, Judson M A. Neurosarcoidosis[J]. Curr Treat Options Neurol, 2013, 15(4):492-504.
[30]
Lower E E, Broderick J P, Brott T G, et al. Diagnosis and management of neurological sarcoidosis[J]. Arch Intern Med, 1997, 157(16):1864-1868.
[31]
Cohen A F, Bouvry D, Galanaud D, et al. Long-term outcomes of refractory neurosarcoidosis treated with infliximab[J]. J Neurol, 2017, 264(5):891-897.
[32]
Bruns F, Pruemer B, Haverkamp U, et al. Neurosarcoidosis: an unusual indication for radiotherapy[J]. Br J Radiol, 2004, 77(921):777-779.
[33]
Hoitsma E, Faber C G, Drent M, et al. Neurosarcoidosis: a clinical dilemma [J]. Lancet Neurol, 2004, 3(7):397-407.
2018, Vol. 29 
